Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.

Summary

This study will explore whether ivabradine lowers heart rate, and thus improves exercise capacity, in survivors of lymphoma who have an elevated resting heart rate as a side effect of prior radiation treatment. The drugs involved in this study are: * Ivabradine * Placebo

Timeline

Start

2018-02-27

Primary completion

2020-11-18

Completion

2020-11-18

Outcome

Met primary endpoint

Stopped (Business): “Funding terminated”

registry MEDIAN Ivabradine: -13 (-25 to 0) bpm NCT03137537 ↗

registry analysis (superiority test); Ivabradine vs Placebo Oral Tablet; p <0.001; Wilcoxon (Mann-Whitney) NCT03137537 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ivabradine	Small molecule	—	Oral

Indications